A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT02591095 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant or Refractory Ovarian Cancer

Interventions

DRUG: ABT-263

Sponsor

Centre Francois Baclesse

Collaborators

[object Object]
[object Object]